Literature DB >> 8143967

A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.

J P Villeneuve1, M Desrochers, C Infante-Rivard, B Willems, G Raymond, M Bourcier, J Côté, G Richer.   

Abstract

BACKGROUND/AIMS: Prospective studies from the Far East and Alaska have shown an increased mortality from cirrhosis and/or hepatocellular carcinoma in asymptomatic hepatitis B virus (HBV) carriers. The magnitude of this risk in apparently healthy North American carriers remains undefined.
METHODS: The outcomes of 317 asymptomatic hepatitis B surface antigen-positive carriers from the Montreal area were examined after 16 years of follow-up. A majority of carriers were of French Canadian origin, were positive for antibody to hepatitis B e antigen, and had normal serum transaminase levels; institutionalization in orphanages as infants or children was the most important epidemiological risk factor, suggesting horizontal transmission of HBV during childhood.
RESULTS: At follow-up, mean age was 46 +/- 8 years; 3 carriers had died of HBV-related cirrhosis, 1 of alcoholic cirrhosis, and 9 of causes unrelated to liver disease. No carrier died of hepatocellular carcinoma; had the risk of hepatocellular carcinoma been similar to that reported from the Far East and Alaska, 17 cases of hepatocellular carcinoma-related deaths would have been expected. During follow-up, the annual negativation rate for hepatitis B surface antigen was 0.7%.
CONCLUSIONS: In asymptomatic HBV carriers from Montreal, a majority are "healthy" carriers and remain asymptomatic after 16 years of follow-up and the risk of death from HBV-related cirrhosis and/or hepatocellular carcinoma is low.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143967     DOI: 10.1016/0016-5085(94)90760-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Global alliance on vaccines and immunizations. Save the Children UK had concerns about alliance that went further than report did.

Authors:  Gill Walt; Ruairi Brugha; Mary Starling; R K Ojha; Jacob Abraham; Meenakshi Khosla; Jacob M Puliyel
Journal:  BMJ       Date:  2002-04-20

2.  Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse.

Authors:  Vineet Tyagi; Saroj K Singh; Ashu Sawhney; Vikas Taneja; Jacob M Puliyel
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.

Authors:  Fen-Yu Ren; Xi-Xu Piao; Ai-Lian Jin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

5.  Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.

Authors:  Rania A Tohme; Lisa Bulkow; Chriss E Homan; Susan Negus; Brian J McMahon
Journal:  J Clin Virol       Date:  2013-08-16       Impact factor: 3.168

6.  Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".

Authors:  Stephanos J Hadziyannis
Journal:  Hepatol Int       Date:  2007-06       Impact factor: 6.047

Review 7.  Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

Authors:  Matthias Girndt
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom.

Authors:  Jihyun An; Han Chu Lee
Journal:  Hepat Oncol       Date:  2015-07-28

9.  Chronic hepatitis B infection in Canada.

Authors:  G Y Minuk; J Uhanova
Journal:  Can J Infect Dis       Date:  2001-11

10.  Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.

Authors:  Robert J Wong; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.